SA JOURNAL OF DIABETES & VASCULAR DISEASE RESEARCH ARTICLE VOLUME 21 NUMBER 1 • November 2024 29 of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arteriosclerosis Thrombosi Vasc Biol 2017; 37(2): 191–204. 13. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–125. 14. Vargas-Uricoechea H, Cáceres-Acosta MF. Control of blood pressure and cardiovascular outcomes in type 2 diabetes. Open Med 2018; 13: 304–323. 15. Wong ND, Patao C, Malik S, Iloeje U. Preventable coronary heart disease events from control of cardiovascular risk factors in US adults with diabetes (projections from utilizing the UKPDS risk engine). Am J Cardiol 2014; 113(8): 1356–1361. 16. Heckbert SR, Rutter CM, Oliver M, Williams LH, Ciechanowski P, Lin EH, et al. Depression in relation to long-term control of glycemia, blood pressure, and lipids in patients with diabetes. J Gen Intern Med 2010; 25(6): 524–529. 17. Katon WJ, Lin EH, Russo J, Von Korff M, Ciechanowski P, Simon G, et al. Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med 2004; 19(12): 1192–1199. 18. Akpalu J, Yorke E, Ainuson-Quampah J, Balogun W, Yeboah K. Depression and glycaemic control among type 2 diabetes patients: a cross-sectional study in a tertiary healthcare facility in Ghana. BMC Psychiatry 2018; 18(1): 1–7. 19. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: Int Diabetes Fed. 2019. www.diabetesatlas.org 2019 [Accessed on May 19, 2021] 20. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med 2019; 17(1): 145. 21. Moulton CD, Pickup JC, Ismail K. The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol 2015; 3(6): 461–471. 22. Hackett RA, Steptoe A. Type 2 diabetes mellitus and psychological stress – a modifiable risk factor. Nature Rev Endocrinol 2017; 13(9): 547–560. 23. Do Prado-Lima PS. Medical comorbidities and functioning in depression: a clinical perspective. Medicographia 2014; 36(4): 464–469. 24. Kim SW, Kang HJ, Jhon M, Kim JW, Lee JY, Walker AJ, et al. Statins and inflammation: new therapeutic opportunities in psychiatry Frontiers Psychiatry 2019; 10: 103. 25. Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the hypothalamic–pituitary–adrenocortical stress response. Comprehens Physiol 2016; 6(2): 603–621. 26. Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015; 300: 141–154. 27. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129. 28. Nikkheslat N, Zunszain PA, Horowitz MA, Barbosa IG, Parker JA, Myint AM, et al. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav Immun 2015; 48: 8–18. 29. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32(14): 1769–1818. 30. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. 31. Subramaniapillai M, Chen VC, McIntyre RS, Yang YH, Chen YL. Added burden of major depressive disorder on cardiovascular morbidity and mortality among patients with cardiovascular disease and the modifying effects of antidepressants: A national retrospective cohort study. J Affect Disord 2021; 294: 580–585. 32. Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378(9808): 2013–2020. 33. Köhler O, Gasse C, Petersen L, Ingstrup KG, Nierenberg AA, Mors O, et al. The effect of concomitant treatment with SSRIs and statins: a population-based study. Am J Psychiatry 2016; 173(8): 807–815. 34. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. ICD-10 Version:2019. www.icd.who.int/browse10/2019/en. [Accessed on August 30, 2020] 35. Prescribed Minimum Benefits (PMB) Council for Medical Schemes. CMS PMB ICD-10 CODED LIST 2013 www.medicalschemes.com. [Accessed on May 19, 2021] 36. Anatomical Therapeutic Chemical (ATC) classification https://www.whocc.no/atc/ structure_and_principles/ [Accessed on March 18, 2022] 37. Kim SW, Bae KY, Kim JM, Shin IS, Hong YJ, Ahn Y, et al. The use of statins for the treatment of depression in patients with acute coronary syndrome. Translat Psychiatry 2015; 5(8): e620. 38. Kaulgud R, Nekar M, Sumanth K, Joshi R, Vijayalakshmi P, Desai S, et al. Study of depression in patients with diabetes compared to nondiabetics among elderly population and its association with blood sugar, HbA1c values. Int J Biomed Res 2013; 4: 55–61. 39. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317(7160): 703. 40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008; 359(15): 1577–1589. 41. Masilela C, Pearce B, Ongole JJ, Adeniyi OV, Benjeddou M. Factors associated with glycemic control among South African adult residents of Mkhondo municipality living with diabetes mellitus. Medicine 2020; 99(48): e23467. 42. Naidoo LA, Butkow N, Barnard-Ashton P, Miot J, Libhaber E. Is the risk really shared? A retrospective analysis of healthcare costs of patients with type 2 diabetes mellitus on a capitation model. Value Health Region Issues 2022; 28: 29–37. 43. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. Twenty-fourhour blood pressure-lowering effect of a sodiumglucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebocontrolled SACRA study. Circulation 2019; 139(18): 2089–2097. TELMISARTAN/ AMLODIPINE FDC* INTRODUCING OUR TELMISARTAN/ AMLODIPINE FDC* OFFERS 24 HOUR BLOOD PRESSURE CONTROL2 TELMISARTAN / AMLODIPINE 40/5 mg 40/10 mg 80/5 mg 80/10 mg CONVENIENTLY PACKED IN 30’s TESDYN 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg. Each tablet contains 40, 80 mg telmisartan respectively and 5, 10 mg amlodipine (as amlodipine besylate) respectively. S3 A55/7.1.3/0668, 0669, 0670, 0671. For full prescribing information, refer to the professional information approved by SAHPRA, November 2023. 1) Source: Based on internal analysis by Pharmadynamics (Pty) Ltd using data from the following source: IQVIA TPM MAT April 2024 ATC1 A1A- Brands measured in Units, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved 2) Approved professional information. * Fixed-dose combination. TNB1169/10/2024. CUSTOMER CARE LINE +27 21 707 7000 www.pharmadynamics.co.za ALWAYS ON GUARD
RkJQdWJsaXNoZXIy NDIzNzc=